Drug Trial Radar · NCT07683754
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 4, 2026
Primary completion
Jul 4, 2030
Study completion Aug 28, 2030
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under maintenance aimed to maximizing disease control, optimizing tolerability, and preserving T-DXd as a future therapeutic option, while ensuring participant safety and regulatory compliance in participants with HER2+/HR+ advanced/metastatic breast cancer.
Conditions
- Advanced Breast Cancer
- Metastatic Breast Cancer
- HER2 Positive
- HR Positive
Interventions
Trastuzumab deruxtecanDrug
Upfront treatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle T-DXd Retreatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle \*Dose reductions implemented during Upfront treatment phase will be maintained.
TrastuzumabDrug
Maintenance treatment: One IV infusion Q3W 6 mg/kg on Day 1 of each 21-day cycle
PertuzumabDrug
Upfront treatment: One IV infusion Q3W loading dose of 840 mg, then 420 mg Q3W thereafter on Day 1 of each 21-day cycle Maintenance treatment: One IV infusion Q3W 420 mg on Day 1 of each 21-day cycle
Endocrine TherapyDrug
Aromatase inhibitors or fulvestrant administered as approved product label
PalbociclibDrug
Maintenance treatment: Daily (3 out of 4 weeks, Q4W) oral 125 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) Rate at 24 MonthsTime frame: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Maryland Oncology Hematology, P.A.
Columbia, Maryland · Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology - West Texas
El Paso, Texas · Recruiting
Texas Oncology - San Antonio
New Braunfels, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.